Health Canada has allowed the first clinical trial phases for the transplantation of stem cells to patients suffering from blood-related diseases, such as leukemia, myeloma and lymphoma.
The distinctive feature of these stem cells is that they will have been previously multiplied in a unit of cord blood with the molecule UM171, which was discovered by the teams of Anne Marinier, principal investigator and director of medicinal chemistry at the Institute for Research in Immunology and Cancer (IRIC) at the Université de Montréal, and Dr. Guy Sauvageau, principal investigator at IRIC and hematologist at the Maisonneuve-Rosemont Hospital (CIUSSS de l’Est de l’Île-de-Montréal).
« This is excellent news, claims Dr. Sauvageau. The first clinical trials on a certain number of patients suffering from blood-related diseases will allow us to confirm our hypothesis. It is an important step in the fight against cancer and I would like to highlight the exceptional work of all our teams at IRIC and also at the Hôpital Maisonneuve-Rosemont. »
The Centre of Excellence for Cellular Therapy at the Hôpital Maisonneuve-Rosemont will serve as a production unit for these stem cells, and grafts will then be distributed to patients in the cities of Montreal, Quebec and Vancouver for this first Canadian clinical study.
« We should see the first results in 2016, and if everything goes well, subsequent clinical trial phases will follow. »
Read also: ExCellThera Announces Initiation of Clinical Trial for Cancer Patients (update of December 21st, 2015)
About the Institute for Research in Immunology and Cancer
An ultra-modern research hub and training centre located in the heart of the Université de Montreal, the Institute for Research in Immunology and Cancer (IRIC) was created in 2003 to shed light on the mechanisms of cancer and discover new, more effective therapies to counter this disease. IRIC operates according to a model that is unique in Canada. Its innovative approach to research has already led to discoveries that will, over the coming years, have a significant impact on the fight against cancer. For further information
About the Hôpital Maisonneuve-Rosemont and the CIUSSS de l’Est-de-l’île-de-Montréal
The Centre intégré universitaire de santé et de services sociaux de l’Est-de-l’Île-de-Montréal (CIUSSS-Est) includes Hôpital Maisonneuve-Rosemont, Hôpital Santa Cabrini, the Canadian-Polish Welfare Institute, the Institut universitaire en santé mentale de Montréal, as well as the CSSS de Saint-Léonard et Saint-Michel, the CSSS de la Pointe-de-l’Île, and the CSSS Lucille-Teasdale.
Affiliated with the Université de Montréal, the Hôpital Maisonneuve-Rosemont (HMR) has been a major institution for care, teaching and research since 1954.
About the Centre of Excellence for Cellular Therapy
The Centre of Excellence for Cellular Therapy (CETC) at the Maisonneuve-Rosemont Hospital is a set of laboratories devoted to the manipulation of human cells for therapeutic purposes in humans. The objective of CETC is to spearhead efforts in regenerative medicine and cellular therapy in Canada. For further information
Communication and media relations advisor
Institute for Research in Immunology and Cancer│IRIC
Université de Montréal